Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

Georgina V. Long,Victoria Atkinson,Jonathan Cebon,Michael B. Jameson,Bernie M. Fitzharris,Catriona M. McNeil,Andrew G. Hill,Antoni Ribas,Michael B. Atkins,John A. Thompson,Wen-Jen Hwu,F. Stephen Hodi,Alexander M. Menzies,Alexander Guminski,Richard Kefford,Xinxin Shu,Scot Ebbinghaus,Nageatte Ibrahim,Matteo S. Carlino

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

2016

Georgina V. Long
Victoria Atkinson
Jonathan Cebon
Michael B. Jameson
Bernie M. Fitzharris
Catriona M. McNeil
Andrew G. Hill
Antoni Ribas
Michael B. Atkins
John A. Thompson
Wen-Jen Hwu
F. Stephen Hodi
Alexander M. Menzies
Alexander Guminski
Richard Kefford
Xinxin Shu
Scot Ebbinghaus
Nageatte Ibrahim
Matteo S. Carlino

9506Background: Pembro (MK-3475), an anti–PD-1 antibody that prevents PD-1 from binding to its ligands, PD-L1 and PD-L2, is approved in several countries for treating advanced melanoma. In KEYNOTE-...

Keywords:

Ipilimumab
Cohort
Melanoma
Pembrolizumab
Physical therapy
Medicine
Internal medicine
Oncology
Pathology
advanced melanoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations